Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 14

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
2,527 5,152 Total property and equipment378,343 375,615 Less: accumulated depreciation and amortization (145,809)(122,967)Property and equipment, net$232,534 $252,648 Intangible Assets, NetSeptember 30, 2025December 31, 2024Remaining Useful Life in YearsGrossCarryingAmountAccumulatedAmortizationIntangibles,NetGrossCarryingAmountAccumulatedAmortizationIntangibles,NetTechnology licenses9.0$22,504 $(9,124)$13,380 $22,504 $(8,016)$14,488 Developed technology6.352,639 (1,326)51,313 1,000 (92)908 Customer relationships0.2945 (940)5 945 (918)27 Assembled workforce0.71,328 (1,267)61 1,328 (1,080)248 Intangible assets, net$77,416 $(12,657)$64,759 $25,777 $(10,106)$15,671 During the three months ended September 30, 2025, the Company recorded developed technology of $51.6 million and assembled workforce of $0.7 million in connection with the Scale acquisition. Subsequently, the Company recorded an impairment charge of $0.7 million related to the assembled workforce during the same period. The amortization of developed technology is recorded in cost of revenue. See Note 3, Asset Acquisition, for details related to intangibles acquired.

12

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

Compensation and Related BenefitsAccrued compensation and related benefits were comprised of the following (in thousands):September 30,2025December 31,2024Accrued payroll and related costs$6,420 $2,970 Accrued bonus22,495 21,859 Accrued commissions3,779 5,938 Other4,390 2,848 Accrued compensation and related benefits$37,084 $33,615 Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities were comprised of the following (in thousands):September 30,2025December 31,2024Legal and related costs$3